Jupiter Asset Management Ltd. Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• Jupiter Asset Management Ltd. has acquired a new position in Halozyme Therapeutics by purchasing 60,262 shares valued at approximately $3.85 million.
• Insider trading has seen CEO Helen Torley sell 20,000 shares at an average price of $56.43, leading to a 2.65% decrease in her ownership.
• Analyst ratings for Halozyme show a mix of opinions, with two sell ratings, six holds, and four buy ratings, while the average target price sits at $62.70.

Jupiter Asset Management Ltd. bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 60,262 shares of the biopharmaceutical company's stock, valued at approximately $3,845,000.

Several other institutional investors have also recently made changes to their positions in the company. Capital World Investors purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $35,773,000. D. E. Shaw & Co. Inc. increased its stake in Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after purchasing an additional 524,802 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Halozyme Therapeutics during the fourth quarter worth $21,838,000. LSV Asset Management grew its position in shares of Halozyme Therapeutics by 41.9% in the first quarter. LSV Asset Management now owns 895,191 shares of the biopharmaceutical company's stock valued at $57,122,000 after purchasing an additional 264,130 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in Halozyme Therapeutics by 280.4% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 357,579 shares of the biopharmaceutical company's stock valued at $17,096,000 after acquiring an additional 263,570 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wells Fargo & Company upped their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday. Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Hold" and a consensus price target of $66.40.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $41,403,763.17. The trade was a 2.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 60,000 shares of company stock worth $3,262,400 over the last three months. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

HALO traded down $0.22 during trading on Thursday, hitting $62.10. The stock had a trading volume of 2,070,496 shares, compared to its average volume of 1,953,332. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.50. The firm has a market capitalization of $7.65 billion, a P/E ratio of 14.21, a PEG ratio of 0.41 and a beta of 1.17. The company's 50-day moving average price is $55.69 and its 200 day moving average price is $57.83.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 142.12%. The firm's revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.91 earnings per share. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.